Table 4.

Efficacy ranking of treatments at PASI 90 or PASI75 across network meta-analyses

ADA adalimumab, BRO brodalumab, CZP certolizumab pegol, ETN etanercept, GUS guselkumab, IFX infliximab, IXE ixekizumab, N not reported, PASI psoriasis area severity index, RIS risankizumab, SEC secukinumab, TIL tildrakizumab, UST ustekinumab, WB weight-based dosing, Y reported. Green denotes treatments ranked 1–3, orange 4–6, and grey 7–9. Treatments in brackets are statistically significantly less efficacious

^aPaper considered this approximately the same rank (reported "ustekinumab ≈ adalimumab ≈ etanercept" based on PASI 75 in spite of results OR for ustekinumab vs. etanercept 1.94 (95% CrI 1.31, 3.01)

^bThe multinomial probit model used in this analysis ensures that the rankings observed at PASI 75 will apply for PASI 90

^cReported as “clear/nearly clear” but input data related to PASI 90 or PGA 0/1

^dBased on maximum area under the curve

^eBased on outcomes at week 12